Cellebrite Revolutionizes Investigative Workflow with Groundbreaking End-to-End Platform to Solve More Cases Faster
January 16 2024 - 8:30AM
Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in premier
Digital Investigative solutions for the public and private sectors,
today announced Case-to-Closure (C2C), an expanded end-to-end
platform for examiners and investigators to solve cases faster and
more defensibly to accelerate justice around the world.
“Cellebrite C2C is our mission in action. This
platform provides law enforcement with a new industry standard for
excellence in examination and investigation and will equip
professionals with a broader range of capabilities to clear
backlogged cases like never before,” said Lisa Cole, Chief
Marketing Officer at Cellebrite. “This platform will enable both
public and private sector customers around the globe to accelerate
their investigations, protect and save more lives across global
communities. Building on our rich history for game-changing
innovation, we are proud to be both the first, and the most tried
and tested technology leaders in the Digital Investigation
space.”
As corporate professionals and law enforcement
digital forensic units increasingly face overwhelming volumes of
devices and data that threaten the speed and effectiveness of
investigations, C2C offers multiple breakthrough technology
solutions:
- Cellebrite Inseyets is an enhanced,
automated digital forensics software technology designed to
transform access, extraction and decoding of digital data across
the broadest range of mobile phones and other digital sources.
Cellebrite Inseyets equips our customers with the capabilities to
surface more actionable insights faster from full file system
extractions, including cloud data—minimizing the risk of leaving
important evidence behind. Powered by market leading UFED and PA
Ultra technology, Cellebrite Inseyets is designed to reduce
examination time by up to 40% and allow agencies of all sizes to
access up to 60% more data. It also enables examiners to expertly
triage devices to determine relevancy to an investigation, saving
precious time and maximizing scarce resources.Built with an
enhanced workflow automation module, Forensic Labs and
Investigative Units can accelerate data extraction and
time-to-evidence, giving them a complete view of their
investigation data, increasing efficiency, reducing human error and
preserving evidence integrity for court.
- Enhancements to
Cellebrite Pathfinder that connect data points from an unlimited
amount of sources and gives investigators a big picture view of
links between devices. With a new speech-to-text feature,
investigators can easily locate specific words or phrases related
to their cases that may have been otherwise buried or hidden within
mountains of unstructured data. This enriched viewpoint is critical
to create and complete the case story for investigators whose
success relies on in-depth analysis.
- Additional Cellebrite
Guardian features provide secure evidence storage,
unit collaboration and the necessary chain of custody to ensure
cases are protected from scrutiny. With Guardian, every player in
the investigative process can securely and lawfully access needed
data from anywhere, streamlining the evidentiary process.
You can learn more information about Cellebrite C2C
here.
About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable
its customers to protect and save lives, accelerate justice and
preserve privacy in communities around the world. We are a global
leader in Digital Investigative solutions for the public and
private sectors, empowering organizations in mastering the
complexities of legally sanctioned digital investigations by
streamlining intelligence processes. Trusted by thousands of
leading agencies and companies worldwide, Cellebrite’s Digital
Investigative platform and solutions transform how customers
collect, review, analyze and manage data in legally sanctioned
investigations. To learn more visit us at www.cellebrite.com,
https://investors.cellebrite.com, or follow us on Twitter at
@Cellebrite.
Caution Regarding Forward Looking
Statements
This document includes “forward-looking statements”
within the meaning of the “safe harbor” provisions of the United
States Private Securities Litigation Reform Act of 1995. Forward
looking statements may be identified by the use of words such as
“forecast,” “intend,” “seek,” “target,” “anticipate,” “will,”
“appear,” “approximate,” “foresee,” “might,” “possible,”
“potential,” “believe,” “could,” “predict,” “should,” “could,”
“continue,” “expect,” “estimate,” “may,” “plan,” “outlook,”
“future” and “project” and other similar expressions that predict,
project or indicate future events or trends or that are not
statements of historical matters. Such forward-looking statements
include, but are not limited to, the following: estimated financial
information for fiscal year 2023 and certain statements related to
moving into the final quarter of the year with a compelling value
proposition, attractive prospects to grow our wallet share with
customers, and an increasingly efficient cost structure that
supports ongoing profit improvement; our expectations for a strong,
productive finish to 2023; revenue trending toward the upper half
of our prior full-year 2023 expectations; and our belief that our
continued progress in executing against our strategic priorities
over the coming months will enable us to sustain our momentum into
next year. Such forward-looking statements including those with
respect to 2023 revenue, annual recurring revenue (ARR), adjusted
EBITDA, operating profitability and earnings as well as commentary
associated with future performance, strategies, prospects, and
other aspects of Cellebrite’s business are based on current
expectations that are subject to risks and uncertainties. A number
of factors could cause actual results or outcomes to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to: Cellebrite’s ability
to keep pace with technological advances and evolving industry
standards; Cellebrite’s material dependence on the purchase,
acceptance and use of its solutions by law enforcement and
government agencies; real or perceived errors, failures, defects or
bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain
the productivity of sales and marketing personnel, including
relating to hiring, integrating and retaining personnel; intense
competition in all of Cellebrite’s markets; the inadvertent or
deliberate misuse of Cellebrite’s solutions; failure to manage its
growth effectively; Cellebrite’s ability to introduce new solutions
and add-ons; its dependency on its customers renewing their
subscriptions; the low volume of business Cellebrite conducts via
e-commerce; risks associated with the use of artificial
intelligence; the risk of requiring additional capital to support
the growth of its business; risks associated with higher costs or
unavailability of materials used to create its hardware product
components; fluctuations in foreign currency exchange rates;
lengthy sales cycle for some of Cellebrite’s solutions; near term
declines in new or renewed agreements; risks associated with
inability to retain qualified personnel and senior management; the
security of Cellebrite’s operations and the integrity of its
software solutions; risks associated with the negative publicity
related to Cellebrite’s business and use of its products; risks
related to Cellebrite’s intellectual property; the regulatory
constraints to which Cellebrite is subject; risks associated with
Cellebrite’s operations in Israel, including the ongoing
Israel-Hamas war and the risk of a greater regional conflict; risks
associated with different corporate governance requirements
applicable to Israeli companies and risks associated with being a
foreign private issuer and an emerging growth company; market
volatility in the price of Cellebrite’s shares; changing tax laws
and regulations; risks associated with joint, ventures,
partnerships and strategic initiatives; risks associated with
Cellebrite’s significant international operations; risks associated
with Cellebrite’s failure to comply with anti-corruption, trade
compliance, anti-money-laundering and economic sanctions laws and
regulations; risks relating to the adequacy of Cellebrite’s
existing systems, processes, policies, procedures, internal
controls and personnel for Cellebrite’s current and future
operations and reporting needs; and other factors, risks and
uncertainties set forth in the section titled “Risk Factors” in
Cellebrite’s annual report on Form 20-F filed with the SEC on April
27, 2023 and in other documents filed by Cellebrite with the U.S.
Securities and Exchange Commission (“SEC”), which are available
free of charge at www.sec.gov. You are cautioned not to place undue
reliance upon any forward-looking statements, which speak only as
of the date made, in this communication or elsewhere. Cellebrite
undertakes no obligation to update its forward-looking statements,
whether as a result of new information, future developments or
otherwise, should circumstances change, except as otherwise
required by securities and other applicable laws.
Media
Victor Cooper Sr. Director of Corporate
Communications + Content
Operations Victor.cooper@cellebrite.com +1
404.804.5910
Investor Relations
Andrew Kramer Vice President, Investor
Relations investors@cellebrite.com +1
973.206.7760
Cellebrite Digital Intel... (NASDAQ:CLBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellebrite Digital Intel... (NASDAQ:CLBT)
Historical Stock Chart
From Oct 2023 to Oct 2024